Inhibikase Therapeutics, Inc. · NASDAQ:IKT
ADAR1 Capital Management, LLC reported a 9.90% stake in Inhibikase Therapeutics, Inc. (Schedule 13G/A)
Event Jun 30, 2025 · Filed Aug 14, 2025
ADAR1 Capital Management, LLC reported a 9.90% stake in Inhibikase Therapeutics, Inc., 7,682,503 shares, as a passive investor on Jun 30, 2025. Filed Aug 14, 2025 (Schedule 13G/A).
- Stake
- 9.90%
- Shares
- 7,682,503
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 3 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| ADAR1 Capital Management, LLC | 9.90% | 7,682,503 |
| ADAR1 Capital Management GP, LLC | 9.90% | 7,737,694 |
| Daniel Schneeberger | 9.90% | 7,682,503 |
Source
Related
- Inhibikase Therapeutics, Inc.
- ADAR1 Capital Management, LLC
- Inhibikase Therapeutics, Inc. shareholders
- Schedule 13G/A · ADAR1 Capital Management, LLC · May 15, 2026
- Schedule 13G/A · ADAR1 Capital Management, LLC · Feb 17, 2026
- Schedule 13G · ADAR1 Capital Management, LLC · Feb 14, 2025
- Schedule 13G/A · Perceptive Advisors LLC · Aug 14, 2026
- Schedule 13G/A · Nantahala Capital Management, LLC · Aug 14, 2026
- Schedule 13G/A · Sands Capital Life Sciences Pulse Fund II, L.P. · Aug 13, 2026
- Form 4 · Berman Dennis N · Jul 31, 2026
- Form 4 · RA Capital Healthcare Fund LP · Jul 31, 2026